Nutrition plus resmetirom for MASH in NYC
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding a special nutrition plan to the medication resmetirom helps people with MASH (a type of fatty liver disease) and moderate liver scarring. It's for New York City residents who are starting resmetirom anyway.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You live in one of the five New York City boroughs (Manhattan, Brooklyn, Queens, The Bronx, or Staten Island).
- You are between 18 and 75 years old.
- You have non-cirrhotic MASH with moderate to advanced liver scarring (stage F2 or F3).
- You are starting or have recently started resmetirom as part of your regular care.
- You do not have cirrhosis, severe liver disease, or other chronic liver conditions.
- You are not pregnant or breastfeeding, and you avoid high alcohol intake.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This trial tests an experimental gene therapy (VV-14303) given as a single injection into the muscle to treat MASH, a common type of fatty liver disease with inflammation. The study will check if the treatment is safe and helps improve liver health.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
This trial tests a new drug, IMM-H014, for a liver condition called MASH (metabolic dysfunction-associated steatohepatitis). It looks at how well people tolerate the drug and how it works in the body. This might help if you have fat buildup in your liver along with other health issues like high blood pressure, diabetes, or high cholesterol.
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.